Based on tumor heterogeneous characteristics, BC is classified according to several molecular subgroups: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), normal and basal-like based on immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PR), HER2 and proliferation marker Ki-67. This evidence concerns the gene ESR1 and neoplasm.